Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | Avelumab maintenance for urothelial cancer

Thomas Powles, MBBS, MCRP, Barts Cancer Institute, London, UK, discusses the use of avelumab maintenance in urothelial cancer (UC) as presented at ESMO 2020. Prof. Powles summarizes the use of avelumab first-line (1L) maintenance for patients with advanced UC, highlighting data from the Phase III JAVELIN Bladder 100 trial (NCT02603432). This study showed that avelumab 1L maintenance and best supportive care (BSC) prolonged the overall survival (OS) vs BSC alone in UC patients free from disease progression following 1L induction chemotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.